ObsEva Phase II trial shows meaningful increase in pregnancy and live birth rates

The results of ObsEva’s Phase II clinical trial of OBE001 (nolasiban) showed improvement in clinical pregnancy and live birth rates in women undergoing embryo transfer (ET) following in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI). The trial was designed to assess the safety and efficacy of a range of doses of OBE001, an oral oxytocin receptor antagonist, compared to placebo.